ARPharM and its members are conscious of the importance of providing accurate, fair and objective information about medicinal products so that rational decisions can be made as to their use. The Code of Ethics of the Research-based Pharmaceutical Industry in Bulgaria fits into the general framework established by the EU Directive 2001/83/EC (Title VIII & Title VIIIa – p. 49 to 54), the Bulgarian Law on Medicinal Products and the EFPIA Code on the Promotion of prescription-only medicines to, and interactions with, Healthcare Professionals which all lay down provisions on the information and advertising of medicines. The Code of Ethics of ARPharM seeks to ensure that pharmaceutical companies conduct such promotion and interactions with prescribers in a truthful manner, avoiding deceptive practices and potential conflicts of interest with healthcare professionals, and in compliance with applicable laws and regulations.
HCP (Healthcare professional) includes any member of the medical, dental, pharmacy or nursing professions or any other person who in the course of his/her professional activities may prescribe, purchase, supply or administer a medicinal product.
Any practice that might create confusion about the real scientific and educational purpose of scientific events sponsored by industry or to which industry sponsors HCPs should not be tolerated.
Article 10 of the Code of Ethics of ARPharM.
Through e4ethics ARPharM supports monitoring of third-party organised (a non-member company or organisation, which has not undertaken to comply with the Code), national events in Bulgaria, by pre-assessing events with regard to the ARPharM Code of Ethics. Companies belonging to the ARPharM membership are encouraged to consult e4ethics and should be mindful of the rules and provisions applying when deciding sponsoring, participating or collaborating in an event.
ARPharM will initially focus on major national events taking place in Bulgaria – i.e. events which are expected to attract more than 50 participants. Each event will be assessed with regard of common standards applicable, in particular with respect to provisions included in the ARPharM Code of Ethics Article 9.